drugset / Trial / NCT01395901

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

NCT01395901

Phase 3 Completed 670 enrolled Helsinn Healthcare SA
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The primary objective of this study is to evaluate the efficacy of a single palonosetron IV dose compared to a single ondansetron IV dose in the prevention of postoperative nausea and vomiting through 24 hours after surgery in children aged from neonates up to less than 17 years undergoing elective surgical procedures requiring general intravenous anesthesia. The secondary objective is to evaluate the safety and tolerability of IV palonosetron in pediatric patients.

Timeline

Start
2011-06
Primary completion
2012-03
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ondansetron Other / unclassified 0.1 mg/kg Intravenous
Comparator Ondansetron Other / unclassified 4 mg Intravenous
Subject Palonosetron Other / unclassified 1 ug/kg Intravenous

Indications

No indication recorded.